IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
Checkpoint adaptation: Keeping Cdc5 in the T-loop.Cell Cycle 2016-12-16;15(24):3339-3340.
Alu repeats as transcriptional regulatory platforms in macrophage responses to M. tuberculosis infection.Nucleic Acids Res. 2016-12-15;44(22):10571-10587.
Improvement of Quantitative Measurements in Multiplex Proteomics Using High-Field Asymmetric Waveform Spectrometry.J. Proteome Res. 2016-12-02;15(12):4653-4665.
MHC class I-associated peptides derive from selective regions of the human genome.J. Clin. Invest. 2016-12-01;126(12):4690-4701.
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.J. Clin. Invest. 2016-12-01;126(12):4569-4584.
Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer.PLoS ONE 2016-11-30;11(11):e0166731.
Systematic chemical-genetic and chemical-chemical interaction datasets for prediction of compound synergism.Sci Data 2016-11-22;3:160095.
Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.Sci Rep 2016-11-22;5:37581.
Discovery of Ibomycin, a Complex Macrolactone that Exerts Antifungal Activity by Impeding Endocytic Trafficking and Membrane Function.Cell Chem Biol 2016-11-17;23(11):1383-1394.
Structural dynamics control the MicroRNA maturation pathway.Nucleic Acids Res. 2016-11-16;44(20):9956-9964.